RGLS up +2.36% percent right now. $RGLS High is at
Post# of 72696
![Avatar](/images/ProfileImages/1260668286_9544_Lucky Jimmy.jpg)
Recent News posted below.
RGLS Regulus Therapeutics Inc Recent Headline News
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 106.85 (+0.40), ACHN: 12.92 (+2.81), RGLS: 20.94 (-1.14), ABBV: 63.73 (+2.23)
Regulus Therapeutics (RGLS) Strong On High Relative Volume Today
at The Street - Mon Nov 10, 9:04AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 20.93 (-1.15)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.71 (+0.51), GILD: 106.85 (+0.40), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.71 (+0.51), GILD: 106.85 (+0.40), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.71 (+0.51), GILD: 106.84 (+0.39), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.71 (+0.51), GILD: 106.84 (+0.39), ACHN: 12.91 (+2.80), CNAT: 6.99 (+0.14), MRK: 58.79 (-0.55), LGND: 55.20 (+1.26), RGLS: 20.93 (-1.15), ABBV: 63.73 (+2.23), BMY: 58.73 (+0.41), ENTA: 44.12 (+0.79)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 326.58 (+5.83), ALNY: 99.14 (+3.30), ISIS: 47.19 (+2.60), OGXI: 2.17 (-0.01), TEVA: 58.04 (+0.34), RGLS: 20.93 (-1.15), GSK: 45.15 (+0.24), SNY: 46.29 (+0.60)
Regulus to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. The conference is being held at the Arizona Biltmore in Phoenix, AZ.
RGLS: 20.93 (-1.15)
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 31.79 (-0.09), RGLS: 20.93 (-1.15), WAB: 89.48 (+0.21)
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)